



ASX ANNOUNCEMENT

6 November 2014

Australian Patent for Core Cynata Technology

Melbourne, Australia; 6 November 2014: Stem cell and regenerative medicine company Cynata Therapeutics Ltd (ASX: CYP) announced today that a key patent application behind its Cymerus™ stem cell technology has received a Notice of Acceptance from IP Australia. The patent application, entitled “Generation of clonal mesenchymal progenitors and mesenchymal stem cell lines under serum-free conditions” is owned by the Wisconsin Alumni Research Foundation (WARF) and among the intellectual property licensed exclusively by WARF to Cynata. The inventors are Dr Maxim Vodyanyk and Professor Igor Slukvin, founders, advisors and significant shareholders of Cynata.

“This important patent application covers a core element of our proprietary stem cell manufacturing technology,” said Dr Ross Macdonald Cynata’s Chief Executive Officer. “We continue to strengthen Cynata’s already comprehensive patent estate relating to the scalable manufacture of consistent, high quality mesenchymal stem cell (MSC) therapeutic products targeting a range of major diseases worldwide”.

The company anticipates that the Australian patent will be granted in January 2015.

Media contacts: Dr Ross Macdonald, CEO: Tel: 0412 119343; email ross.macdonald@cynata.com
Dr Stewart Washer, Executive Chairman: Tel: 0418 288212; email stewart.washer@cynata.com

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Ltd (ASX: CYP) is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology seeks to address a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ does so through the production of a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ MCA platform provides a source of MSCs that is independent of donor limitations and provides a potential “off-the-shelf” stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.

Cynata Therapeutics Limited – Suite 1, 1233 High Street, Armadale, Victoria 3143 - PO Box 7165, Hawthorn North, Victoria 3122 **T:** + 613 9824 5254 **F:** + 613 9822 7735 **E:** admin@cynata.com
W: www.cynata.com **ABN** - 98 104 037 372